Oligonucleotide delivery systems for camptothecins

Details Oligonucleotide delivery systems for camptothecins Oligonucleotide delivery systems for camptothecins

2005-05-24

2005-05-24

Nguyen, Dave Trong (Department: 1632)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S023000, C546S048000

Reexamination Certificate

active

06897200

ABSTRACT:
Camptothecin drugs are stabilized in their antitumor active lactone form by complexation with an oligonucleotide including RNA or catalytic RNA. The oligonucleotide-camptothecin drug complex may be incorporated within a macromolecular assembly including both viral and non-viral oligonucleotide vectors. The invention allows combination gene and camptothecin drug therapy.

REFERENCES:
patent: 5276019 (1994-01-01), Cohen et al.
patent: 5447936 (1995-09-01), Hausheer et al.
patent: 5552156 (1996-09-01), Burke
patent: 5583034 (1996-12-01), Green
patent: 5604233 (1997-02-01), Hausheer et al.
patent: 5651986 (1997-07-01), Brem et al.
patent: 5674873 (1997-10-01), Hausheer et al.
patent: 5677286 (1997-10-01), Shull et al.
patent: 5714170 (1998-02-01), Baserga et al.
patent: 5726181 (1998-03-01), Hausheer et al.
patent: 5736156 (1998-04-01), Burke
patent: 5834012 (1998-11-01), Perez-Soler et al.
patent: 6407117 (2002-06-01), Bouscarel et al.
Verma, Nature, vol. 389, 1997, 239-242.*
Pantazis, J. Biomedical Science, 6, 1, 1-7, 1999.*
Yang et al., J. Am. Chem. Soc. 120, 2979-2980, Published on Web, Mar. 12, 1998.*
Chourpa (Specgtroscopy of Bviological Molecules: Modern Trends, [European Conferenceon Spectroscopy of Biological Molecules], 7th, Madrid, 1997.*
Matteucci (J. Am. Chem. Soc. 1997, vol. 119, 6939-6940).*
Schaack et al., J. Virology, vol. 64, No. 1, 78-85, 1990.*
Jaxel et al., Effect of Local DNA sequence on Topoisomerase I Cleavage in the Presence or Absense of Camptothecin. The Journal of Biological Chemistry. Oct. 25, 1991, vol. 266, No. 30, pp. 20418-20423, especially the abstract.
Database Caplus on STN, AN 1997:725569, Fleury et al. Conformation and mechanism in DNA-topoisomerase I as a target of antitumor drugs: optical spectroscopy approach. Spectrosc. Biol. Mol.; Mod. Trends. 1997, Eur. Conf. 7th, Conference Abstct.
Leteurtre et al. Specific Interaction of Camptothecin, a Topoisomerase I Inhibitor, with Guanine Residues of DNA detected by Photoactivation at 365 nm. Biochemistry. 1993, vol. 32, pp. 8955-8962, especially abstract.
Giovanella, et al., DNA Topoisomerase I-Targeted Chemotherapy of Human Colon Cancer in Xenografts, Science 246: 1046-1048 (Washington, DC) (1989).
Madden, T.D., Burke, T.G., Redelmeier, T.E. and Bally, M.B., “Encapsulation of Topotecan in Lipid-Based Carriers: Evaluation of Drug Stability and Plasma Elimination in a Murine Model”, Proc. Am. Soc. Clin. Oncol., 17: 196a (1998).

Affiliated with

Also associated with

Rating

Oligonucleotide delivery systems for camptothecins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oligonucleotide delivery systems for camptothecins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotide delivery systems for camptothecins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3425436